Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 196 AL 210

Current opinion in Alzheimer's disease therapy by nanotechnology-based approaches

Ansari SA, Satar R, Perveen A, Ashraf GM.

Curr Opin Psychiatry. 2017 Mar;30(2):128-135. doi: 10.1097/YCO.0000000000000310.

The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial

Carotenuto A, Rea R, Traini E, Fasanaro AM, Ricci G, Manzo V, Amenta F.

J Alzheimers Dis. 2017;56(2):805-815. doi: 10.3233/JAD-160675.

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease

Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS.

J Neuroinflammation. 2017 Jan 3;14(1):1. doi: 10.1186/s12974-016-0779-0.

A Perspective on Crocus sativus L. (Saffron) Constituent Crocin: A Potent Water-Soluble Antioxidant and Potential Therapy for Alzheimer's Disease

Finley JW, Gao S.

J Agric Food Chem. 2017 Feb 8;65(5):1005-1020. doi: 10.1021/acs.jafc.6b04398. Epub 2017 Jan 31.

Solanezumab: too late in mild Alzheimer's disease?

The Lancet Neurology.

Lancet Neurol. 2017 Feb;16(2):97. doi: 10.1016/S1474-4422(16)30395-7.

Acute renal failure caused by cilostazol in a patient with Alzheimer's disease

Nomoto H, Matsubara Y, Ichimiya Y, Arai H.

Geriatr Gerontol Int. 2017 Jan;17(1):171-172. doi: 10.1111/ggi.12760.

Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial

Decourt B, Drumm-Gurnee D, Wilson J, Jacobson S, Belden C, Sirrel S, Ahmadi M, Shill H, Powell J, Walker A, Gonzales A, Macias M, Sabbagh MN.

Curr Alzheimer Res. 2017;14(4):403-411. doi: 10.2174/1567205014666170117141330.

Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease

Hull M, Sadowsky C, Arai H, Le Prince Leterme G, Holstein A, Booth K, Peng Y, Yoshiyama T, Suzuki H, Ketter N, Liu E, Ryan JM.

Curr Alzheimer Res. 2017;14(7):696-708. doi: 10.2174/1567205014666170117101537.

It is not only memory: effects of sensecam on improving well-being in patients with mild alzheimer disease

Silva AR, Pinho MS, Macedo L, Moulin C, Caldeira S, Firmino H.

Int Psychogeriatr. 2017 May;29(5):741-754. doi: 10.1017/S104161021600243X. Epub 2017 Jan 26.

Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Sepehry AA, Sarai M, Hsiung GR.

Can J Neurol Sci. 2017 May;44(3):267-275. doi: 10.1017/cjn.2016.426. Epub 2017 Feb 2.

Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial

Jia J, Wei C, Jia L, Tang Y, Liang J, Zhou A, Li F, Shi L, Doody RS.

J Alzheimers Dis. 2017;56(4):1495-1504. doi: 10.3233/JAD-161117.

Nanotechnology for Alzheimer Disease

Leszek J, Md Ashraf G, Tse WH, Zhang J, Gasiorowski K, Avila-Rodriguez MF, Tarasov VV, Barreto GE, Klochkov SG, Bachurin SO, Aliev G.

Curr Alzheimer Res. 2017;14(11):1182-1189. doi: 10.2174/1567205014666170203125008.

Galantamine Response Associates with Agitation and the Prefrontal Cortex in Patients with Alzheimer's Disease

Nakayama S, Suda A, Nakanishi A, Motoi Y, Hattori N.

J Alzheimers Dis. 2017;57(1):267-273. doi: 10.3233/JAD-160902.

Google Calendar Enhances Prospective Memory in Alzheimer's Disease: A Case Report

El Haj M, Gallouj K, Antoine P.

J Alzheimers Dis. 2017;57(1):285-291. doi: 10.3233/JAD-161283.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias